CY
CYYNF.US Cynata Therapeutics Limited
- Market cap
- USD 2.42M
- P/E
- -
- P/B
- 0.86x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is CYYNF.US undervalued?
Graham numberThe Graham number of Cynata Therapeutics Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cynata Therapeutics Limited fundamental analysis
No fundamental analysis for Cynata Therapeutics Limited yet.
Cynata Therapeutics Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cynata Therapeutics Limited
Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of a proprietary induced pluripotent stem cell (iPSC)-based platform technology under the Cymerus name in Australia. The company develops CYP-004, an iPSC-derived mesenchymal stem cell (MSC) product candidate for intra-articular injection that has completed Phase 3 clinical trial for the treatment of osteoarthritis; CYP-001, an iPSC-derived MSC product candidate for …
Full company profileCynata Therapeutics Limited financial statements
Cynata Therapeutics Limited annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 1.75M | 1.38M | 1.31M | 7.01M | 1.55M | 7.77M | 1.65M | 2.32M | 1.89M | 1.71M |
| Gross Profit | 1.47M | 1.10M | 1.03M | 6.73M | 1.27M | 7.49M | 1.37M | 2.03M | 1.89M | 1.71M |
| Operating Income | -6.33M | -6.13M | -10.1M | -10.5M | -5.81M | -4.29M | -13.0M | -8.81M | -8.12M | -10.0M |
| EBITDA | -6.05M | -5.85M | -9.78M | -10.2M | -8.80M | -13.6M | -16.3M | -9.96M | -9.33M | -7.71M |
| Net Income | -4.55M | -4.57M | -8.47M | -3.64M | -7.69M | -5.45M | -14.3M | -9.74M | -9.39M | -9.25M |
| EPS | -0.06 | -0.05 | -0.08 | -0.03 | -0.06 | -0.04 | -0.10 | -0.05 | -0.05 | -0.04 |
| Balance Sheet | ||||||||||
| Total Assets | 14.3M | 16.1M | 12.2M | 17.5M | 30.0M | 26.5M | 19.0M | 8.39M | 7.20M | 1.35M |
| Total Liabilities | 390K | 746K | 1.28M | 690K | 1.60M | 2.59M | 2.26M | 1.17M | 1.22M | 1.75M |
| Shareholders' Equity | 13.9M | 15.4M | 11.0M | 16.8M | 28.4M | 24.0M | 16.7M | 7.22M | 5.98M | -394K |
| Cash & Short-term Investments | 10.3M | 12.2M | 6.98M | 13.6M | 26.7M | 23.8M | 16.2M | 6.21M | 5.05M | 896K |
| Cash Flow | ||||||||||
| Operating Cash Flow | -4.05M | -4.06M | -6.76M | -3.39M | -5.16M | -3.30M | -14.3M | -9.96M | -8.72M | -6.74M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 50.0K | 0.00 |
| Free Cash Flow | -4.05M | -4.06M | -6.76M | -3.39M | -5.16M | -3.30M | -14.3M | -9.96M | -8.77M | -6.74M |
| Ratios | ||||||||||
| ROE | -32.8% | -29.7% | -77.2% | -21.7% | -27.1% | -22.7% | -85.3% | -135.0% | -157.0% | - |
| ROA | -31.9% | -28.3% | -69.2% | -20.8% | -25.7% | -20.5% | -75.2% | -116.2% | -130.5% | -683.7% |
| Net Profit Margin | -260.4% | -332.0% | -647.4% | -51.9% | -497.4% | -70.1% | -863.0% | -420.8% | -498.1% | -540.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Cynata Therapeutics Limited dividends
Cynata Therapeutics Limited has not paid dividends in the last 10 fiscal years.
Who owns Cynata Therapeutics Limited
- Insiders 18.79%
- Institutions 5.37%
- Public & others 75.84%
- Shares outstanding 337M
- Free float 204M
Cynata Therapeutics Limited company profile
- Company name
- Cynata Therapeutics Limited
- Ticker
- CYYNF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- June
- Address
- 100 Cubitt Street, Cremorne, VIC, Australia, 3121
- Phone
- 61 3 7067 6940
- Website
- cynata.com
About Cynata Therapeutics Limited
Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of a proprietary induced pluripotent stem cell (iPSC)-based platform technology under the Cymerus name in Australia. The company develops CYP-004, an iPSC-derived mesenchymal stem cell (MSC) product candidate for intra-articular injection that has completed Phase 3 clinical trial for the treatment of osteoarthritis; CYP-001, an iPSC-derived MSC product candidate for intravenous use that is in a Phase 1/2 clinical trial for NEREID kidney transplantation; and CYP-006TK, an iPSC-derived MSC topical wound dressing product candidate that completed a Phase 1 trial for the treatment of diabetic foot ulcer. It is also developing pre-clinical pipeline products for asthma, cancer, cardiovascular, sepsis, critical limb ischemia, and idiopathic pulmonary fibrosis indications. The company has a strategic partnership agreement with FUJIFILM Corporation, as well as partnerships with the University of Sydney and Leiden University Medical Center. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was incorporated in 2003 and is based in Cremorne, Australia.
Cynata Therapeutics Limited management
1- Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D.Company Secretary · born 1963